中国COVID-19患者药品不良反应发生率:医院药物警戒系统主动监测研究
该研究利用医院药物警戒系统对长沙第一医院2020年1月17日至2月29日收治的217例COVID-19患者进行回顾性分析,发现药品不良反应发生率为37.8%,以药物性胃肠道紊乱和肝系统紊乱为主,洛匹那韦/利托那韦和乌米诺韦分别可解释63.8%和18.1%的ADR。多因素分析显示住院时长、住院期间用药数量及基础疾病是ADR的独立危险因素。
要点
- COVID-19患者ADR发生率为37.8%,以胃肠道和肝系统紊乱为主。
- 洛匹那韦/利托那韦和乌米诺韦分别可解释63.8%和18.1%的ADR。
- 住院时长、用药数量及基础疾病是ADR的独立危险因素。
核心结论
- COVID-19治疗期间ADR发生率显著较高,CHPS系统主动监测可反映真实世界ADR情况,为临床安全用药提供参考。
研究设计与样本
- 回顾性分析2020年1月17日至2月29日长沙第一医院收治的217例COVID-19患者,采用CHPS主动监测模型检测医院信息系统中的ADR信号。
主要发现
- ADR发生率为37.8%,以药物性胃肠道紊乱和肝系统紊乱为主(23.0% vs. 13.8%)。
- 洛匹那韦/利托那韦和乌米诺韦分别可解释63.8%和18.1%的ADR。
- 96.8%的ADR发生在住院14天内。
- 多因素分析显示住院时长(OR: 2.02; 95%CI 1.03-3.96; P=0.04)、住院期间用药数量(OR: 3.17; 95%CI 1.60-6.27; P=0.001)及基础疾病(OR: 2.07; 95%CI 1.02-4.23; P=0.04)是ADR的独立危险因素。
临床怎么用
- 临床应加强COVID-19患者ADR主动监测,尤其关注胃肠道和肝系统不良反应。
- 对使用洛匹那韦/利托那韦或乌米诺韦的患者应警惕ADR发生。
- 住院时间长、用药数量多及有基础疾病的患者应重点监测ADR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluate the incidence, type, and risk factors associated with adverse drug reactions (ADRs) among patients with coronavirus disease 2019 (COVID-19) by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 patients with COVID-19 admitted to the First Hospital of Changsha in China, from January 17, 2020, to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of the hospital information system. The risk factors for the ADRs were classified using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system. Univariate and multivariate logistic regressions were carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8%). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. There were 96.8% of ADRs that occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (odds ratio (OR): 2.02; 95% confidence interval (CI) 1.03-3.96; P = 0.04), number of drugs used in the hospital (OR: 3.17; 95% CI 1.60-6.27; P = 0.001) and underlying basic diseases (OR: 2.07; 95% CI 1.02-4.23; P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in the clinic.
引用
- Sun J, Deng X, Chen X, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020. PMID: 32324898. doi:10.1002/cpt.1866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。